Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

H358 single cell proteomics by SCOPE2 on a TIMSTOF Flex

ABSTRACT: Single H358 cells analyzed using SCOPE2 on a TIMSTOF Flex mass spectrometer. Bruker .d folders, MGFs, Proteome Discoverer 2.5 and MaxQuant 1.6.17 results are uploaded.

INSTRUMENT(S): timsTOF fleX

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Benjamin Orsburn

PROVIDER: MSV000088144 | MassIVE |

SECONDARY ACCESSION(S): PXD028710

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Human kinome CRISPR knockout screen in H358 parental and sotorasib resistant H358 cells

Project description:A human kinome CRISPR knockout screen in H358 parental and sotorasib-R H358 cells using Addgene pooled libraries (#75314).

2025-10-07 | GSE275314 | GEO

GAPDH inhibition in A549 and H358 lung cancer cells

Project description:Human lung cancer cell lines A549 and H358 were obtained from (Biobank of Medical University of Graz) and cultured in RPMI 1640 (R0883; Sigma) supplemented with 10% fetal bovine serum (FBS; Gibco), 5 mM glutamine and 5 mM Pen Step, and sub-cultured regularly. For siRNA mediated knock-down of GAPDH, 150,000 A549 and H358 cells were seeded in triplicates of a six-well plate and transfected upon reaching ca. 60% confluency with silencerTM siRNA kit targeting GAPDH or non-target control (AM4605; Thermo), using RNAiMax (Thermo) and according to the manufacturer’s instructions for 6-well plate scale. For GAPDH inhibition, 150.000 A549 and H358 cells were seeded in six replicates per condition, then treated with 10 µM koningic acid (KA) or vehicle control (dmso). 48 h post transfection or 24 h post KA treatment, cells were harvested in 500 µl of harvesting solution (80% methanol in 50 mM ammonium acetate with 2.5 mM N-ethylmaleimide) and processed according to one-pot redox approach.

2025-05-12 | PXD061610 | Pride

Development of acquired resistance to sotorasib in NCI-H358 cell line in vitro

Project description:NCI-H358 is a KRAS G12C-mutant non-small lung cancer cell line known to be sensitive to KRAS G12C-inhibitor sotorasib. Here, we aimed to develop sotorasib resistance in H358 and interrogate the resulting sotorasib-resistant cell line (H358-R). The H358-R cell line was created by continuous culturing of the H358 cells in sotorasib (250 nM) until cells grew readily under sotorasib pressure (approximately 2 months). We then performed RNA-seq of the resulting sotorasib-resistant cell line (H358-R) with and without sotorasib pressure, compared to the parental sensitive cell line control (H358). KRAS gene expression level was found to be increased in the sotorasib-resistant line compared with the parental cells, likely representing a mechanism of resistance. The increased KRAS expression level in the resistant cell line was maintained under sotorasib pressure.

2025-09-24 | GSE277630 | GEO

Human kinome CRISPR knockout screen in H358 parental and sotorasib resistant H358 cells

Project description:Human kinome CRISPR knockout screen in H358 parental and sotorasib resistant H358 cells

| PRJNA1150241 | ENA

TIMSTOF analysis of single human NCI-H-358 cells

Project description:SCOPE2 analysis of single human cells treated with a KRAS G12C inhibitor and analyzed on a TIMSTOF Flex instrument

2021-07-08 | MSV000087780 | MassIVE

Expression data from H358

Project description:Tumors that show evidence of epithelial to mesenchymal transition (EMT) have been associated with metastasis, drug resistance, and poor prognosis. EMT may alter the molecular requirements for growth and survival in different contexts, but the underlying mechanisms remain incomplete. Given the heterogeneity along the EMT spectrum between and within tumors it is important to define the requirements for growth and survival in cells with an epithelial or mesenchymal phenotype to maximize therapeutic efficacy. We have established an inducible cell line model in which a tamoxifen regulatable Twist-ER fusion protein is stably expressed in the H358 non-small cell lung cancer cell line. Upon tamoxifen addition, cells undergo EMT and provide a system in which we can compare the growth and survival requirements directly related to EMT, removing confounding factors present when comparing different cell lines. H358 cells stably expressing either GFP or TwistER were treated for 12 days in culture with 100nM 4-hydroxytamoxifen followed by RNA isolation. Three biological replicates of each condition were collected.

2014-01-01 | E-GEOD-52308 | biostudies-arrayexpress

ATAC-seq of NCI-H358 cells treated with KRAS G12C inhibitor sotorasib

Project description:ATAC-seq of sotorasib-resistant NCI-H358 cells treated with sotorasib

2025-07-15 | GSE266309 | GEO

ATAC-seq of sotorasib-resistant H23 and H358 cells treated with TEAD inhibitor GNE-7883

Project description:ATAC-seq of sotorasib-resistant H23 and H358 cells treated with TEAD inhibitor GNE-7883

2023-04-26 | GSE229068 | GEO

Comparison of gene expression in control and BRG1-knockdown H358 cell lines

Project description:Transcription was assessed in the human H358 NSCLC cell line after knockdown of BRG1, one of the mutually exclusive subunits of the SWI/SNF chromatin remodeling complex, by 2 different shRNAs.

2014-09-23 | GSE58542 | GEO

Expression data from H358

2014-01-01 | GSE52308 | GEO